AbbVie to acquire Allergan for $63bn

Analysts have not been overly impressed with the bolt-on acquisitions AbbVie has paid for in recent years; the $21bn it spent acquiring Pharmacyclics and its lymphoma treatment Imbruvica was seen

AZ’s Calquence threatens Imbruvica with new leukaemia data

in its market battle with AbbVie/Johnson &Johnson’s Imbruvica. ... That could give Calquence a leg-up as it tries to make inroads against Imbruvica (ibrutinib), which is already approved as a first- and second-line therapy for CLL and a

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

lymphocytic lymphoma (SLL) who have failed or become intolerant to prior treatment with Johnson &Johnson’s Imbruvica (ibrutinib).

Venclexta plus Gazyva approval adds to non-chemo options in CLL

Roche’s marketing partner AbbVie has a stake in a direct rival, Imbruvica, which it co-markets with J&J. ... In January, Imbruvica gained approval in first line treatment in combination with Gazyva, making it the first non-chemo combination in this

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]